Lupus Australia Briefing

A new study reveals why lupus-associated IRF7 variants persist: they heighten IFN-α production, strengthening antiviral defenses. This evolutionary...

Mindera Health's minimally invasive Dermal Biomarker Patch will track skin molecular changes in a UPenn-led trial of quinacrine for HCQ-nonresponsive CLE patients, aiming to identify responders upfront and confirm its TLR8 antagonism mechanism.

A phase 1 trial of A-319, a CD3×CD19 bispecific antibody, achieved complete peripheral B-cell depletion, 60% DORIS remission and broad immune...

Beeline's oral afimetoran hit its Phase 2 primary endpoint, advancing the drug into pivotal development for two forms of lupus. Australian advocates should monitor upcoming efficacy, safety and access data as the pipeline evolves.

Telitacicept-containing maintenance therapy delivered sustained clinical stability for lupus mesenteric vasculitis, a rare but potentially life-threatening SLE complication with reported mortality rates. Evidence remains limited to this single case.

Advances in genetic analysis now position SLE and immunodeficiency as two sides of the same coin rather than distinct conditions.

• Monogenic lupus...

Beeline Medicines is advancing a lupus candidate acquired from Bristol Myers Squibb, showing that repurposing shelved pharma assets can deliver promising mid-stage results and fresh options for the treatment pipeline.

A Drexel University chapter reviews the clinical presentation, diagnosis, and treatment of SLE-associated cardiovascular diseases, highlighting the need to address these complications as part of routine lupus care.

Adherence to common lupus treatments lowers cardiovascular complications. Young women with lupus already face up to 50 times higher heart attack risk than peers, making patient education on consistent therapy essential for long-term prevention.

A Cleveland chef's Michael Jackson-themed parade float demonstrates how personal survival stories can humanise lupus and spark community solidarity...

Lupus joint involvement hits most patients and ranks high for daily function impact, yet shows a pauci-immune, interferon-driven pattern unlike...

What can PS/PT IgG/IgM testing reliably contribute to thrombosis and pregnancy-risk evaluation in lupus and APS?

• Adds value by correlating with...

A small mechanistic study of twelve women links atypical memory B cells, especially DN2 subtypes, to autoantibody production after COVID-19, tracing...

Oncology-derived B-cell and plasma-cell therapies could reshape lupus care by matching targets to disease biology.

• Autoimmune conditions like SLE...

Dysautonomia affects 6–93% of SLE patients, characterised by sympathetic predominance and reduced HRV.

Preparation helps patients remember key discussion points with their rheumatology team.

• Note any changes since the last visit, even minor ones
  -...

The first COVID-19 wave disrupted care for inflammatory RMDs through widespread visit cancellations and delayed first consultations.

• Treatment...

• BENLYSTA treats adults and children aged 5+ with active SLE or lupus nephritis who are already on other lupus medicines.
• It is not proven safe or...

A new study found that people with SLE and other systemic autoimmune rheumatic diseases identify flares differently from clinicians, especially...

Detailed immune mapping in 64 children with cSLE uncovered distinct B-cell signatures that separate healthy controls from patients, active disease...